Adicet Bio Elects Directors and Approves Key Proposals

Adicet Bio ( (ACET) ) just unveiled an announcement.

On June 11, 2025, Adicet Bio, Inc. held its 2025 Annual Meeting of Stockholders, where three key proposals were voted on. The stockholders elected Chen Schor and Katie Peng as Class I directors for a three-year term, approved the compensation of the company’s named executive officers on a non-binding advisory basis, and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to influence the company’s governance and operational strategies moving forward.

The most recent analyst rating on (ACET) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.

Spark’s Take on ACET Stock

According to Spark, TipRanks’ AI Analyst, ACET is a Underperform.

Adicet Bio faces significant financial challenges and technical weaknesses, with no revenue and ongoing losses as critical concerns. The poor valuation further impacts the stock’s appeal. While the new board appointment is positive, it does not mitigate the substantial risks present in the company’s financials and market performance.

To see Spark’s full report on ACET stock, click here.

More about Adicet Bio

Adicet Bio, Inc. is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in the development of allogeneic gamma delta T cell therapies, aiming to provide innovative treatment options in the oncology sector.

Average Trading Volume: 530,451

Technical Sentiment Signal: Sell

Current Market Cap: $64.91M

Learn more about ACET stock on TipRanks’ Stock Analysis page.